Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)

NCT03566823 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT03566823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03566823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Lead sponsor
Shire
Phase
Phase 3
Overall status
Terminated
Start date
July 17, 2018
Completion date
August 18, 2020
Enrollment
34 (actual)
Sites
145

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease